Hypoxia in anal cancer – a hypothesis generating study using a 15-gene hypoxia classifier
Anna Cecilie Lefèvre,
Denmark
OC-0271
Abstract
Hypoxia in anal cancer – a hypothesis generating study using a 15-gene hypoxia classifier
Authors: Anna Cecilie Lefèvre1, Jan Alsner2, Brita Singers Sørensen2, Trine Tramm3, Kasper Toustrup2, Jens Overgaard2, Karen-Lise Garm Spindler2
1Aarhus University Hospital , Department of Experimental Clinical Oncology, Aarhus, Denmark; 2Aarhus University Hospital, Department of Experimental Clinical Oncology, Aarhus, Denmark; 3Aarhus University Hospital, Department of Pathology, Aarhus, Denmark
Show Affiliations
Hide Affiliations
Purpose or Objective
Purpose:
Tumor hypoxia is related to reduced radiosensitivity in squamous cell
carcinomas (SCC). A 15- gene hypoxia classifier has shown prognostic value in SCC
of the uterine cervix and predictive value for hypoxia modifying treatment in
head and neck SCC (HNSCC). The aim of this study was to investigate the
prognostic value of the 15-gene hypoxia classifier on loco-regional tumor
control in SCC of the anus (SCCA).
Material and Methods
Material:
Diagnostic biopsies were collected from 2016-2019 from 79 newly diagnosed SCCA
patients. All biopsies were formalin fixed and paraffin embedded with
histologically verified, invasive SCC. Each tumors expression of the 15 hypoxia
genes was scored using the method defined by DAHANCA (Toustrup K, Acta Oncol.
2016). A 70% cut-off was used for p16 overexpression. Patients were treated
with high dose chemo-radiotherapy (CRT) with 60 – 64 Gy to tumor and
pathological nodes and 49.5 – 51.2 Gy to CTV, delivered in 30-32 fractions with
concomitant cisplatin-based chemotherapy, according to national Danish
guidelines. Persistent disease was defined as pathological verified SCC < 6
months after CRT, and loco-regional failure was pelvic failure or inguinal node
failure > 6 months after CRT. Fisher’s Exact
test, Cox regression and competing risk analysis were used.
Results
Results:
Classification of the 15 genes was conclusive in all biopsies with 53
(67%) “less” hypoxic tumors and 26 (33%) “more” hypoxic tumors. Comparison of the mean expression levels for the 15 genes
showed similar expression levels for the SCCA samples as for HNSCC and SCC of
the uterine cervix (figure 1) and was unrelated to p16 status. Tumor stages
were 22% T1, 58% T2, 8% T3 and 10% T4, respectively. Node involvement was found
in 23%, and p16 overexpression was detected in 82% of the tumors. Patient and tumor characteristics were equally
distributed between the “less” – and “more” hypoxic groups. After a median follow-up
time of 42 months (range 9 – 66), eight patients (10%) had loco-regional treatment
failure, including five patients with persistent disease. Four of five persistent
patients had a “more” hypoxic tumor, resulting in a significantly increased
risk of persistent disease for “more” hypoxic tumors compared to “less” hypoxic
tumors, p = 0.04. Loco-regional
control is outlined in figure 2, showing a non-significant trend for a relation
between “more“ hypoxic tumors and decreased loco-regional control compared to “less”
hypoxic tumors, with a hazard ratio of 4.48 (0.82 – 24.48) and risk difference
of 11.6%.
Conclusion
Conclusion:
Expression of the hypoxia related genes from the 15-gene hypoxia classifier is
similar in SCC of the uterine cervix, HNSCC and SCCA, and independent of p16
status, indicating that the classifier is representative for hypoxia in SCC in
general. This hypothesis generating study is the first to correlate hypoxia to
outcome in SCCA and the results indicates that clinical studies investigating
hypoxia modifying treatment for SCCA may be relevant.